e-learning
resources
Berlin 2008
Monday, 06.10.2008
Impact of patient education on cost-effectiveness of treatment
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Pharmacoeconomic analysis of beclomethasone/formoterol versus fluticasone/salmeterol in the treatment of moderate-severe asthma in Spain
J. Soto, A. Martin, J. M. Rodriguez Gonzalez-Moro, P. de Lucas (Madrid, Spain)
Source:
Annual Congress 2008 - Impact of patient education on cost-effectiveness of treatment
Session:
Impact of patient education on cost-effectiveness of treatment
Session type:
Thematic Poster Session
Number:
2666
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Soto, A. Martin, J. M. Rodriguez Gonzalez-Moro, P. de Lucas (Madrid, Spain). Pharmacoeconomic analysis of beclomethasone/formoterol versus fluticasone/salmeterol in the treatment of moderate-severe asthma in Spain. Eur Respir J 2008; 32: Suppl. 52, 2666
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
Economic evaluation of beclomethasone/formoterol versus budesonide/formoterol in the treatment of patient with moderate-severe asthma in Spain
Source: Annual Congress 2008 - Impact of patient education on cost-effectiveness of treatment
Year: 2008
Efficacy of salmeterol/fluticasone pMDI
versus
DPI in patients with asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 499s
Year: 2006
Efficacy of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in COPD
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015
Benefit of budesonide/formoterol compared with salmeterol/fluticasone in COPD patients in the morning
Source: Annual Congress 2009 - Healthcare and treatment of COPD
Year: 2009
Mite-induced asthma treatment: Budesonide/formoterol vs. fluticasone/salmeterol
Source: Annual Congress 2010 - Clinical aspects of asthma and allergic respiratory diseases
Year: 2010
Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD
Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD
Year: 2020
Treatment effectiveness and exacerbations during one year with seretide compared to fluticasone propionate and salmeterol in mild-to-moderate asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 176s
Year: 2001
Efficacy and safety of fluticasone/formoterol compared to fluticasone alone in patients with asthma
Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD
Year: 2012
Response to therapy with fluticasone propionate/salmeterol 250/50 or ipratropium/albuterol in population subgroups of patients with COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 336s
Year: 2005
Once-daily NVA237 reduces exacerbations and improves symptoms in COPD patients: A pooled analysis of the GLOW1 and GLOW2 studies
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012
Cost-effectiveness of fluticasone/salmeterol inhaler in treatment of moderate and severe bronchial asthma
Source: Annual Congress 2008 - Comorbid cardiovascular condition and therapy of asthma
Year: 2008
Impact of adherence to treatment with tiotropium co-administered with fluticasone propionate/salmeterol combination in COPD patients
Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease
Year: 2013
A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: The FLAME study
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013
Economic evaluation of salmeterol/fluticasone propionate combination vs budesonide/formoterol in Spain
Source: Annual Congress 2003 - Management of asthma in primary care
Year: 2003
Comparison of spirometric efficacy of fluticasone/salmeterol plus tiotropium and tiotropium alone in moderate COPD
Source: Annual Congress 2009 - New bronchodilators
Year: 2009
Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations
versus
a higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone
Source: Eur Respir J 2006; 28: Suppl. 50, 205s
Year: 2006
A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD
Source: Eur Respir J 2014; 43: 763-772
Year: 2014
Economic evaluation of salmeterol/fluticasone combination
versus
budesonide plus formoterol in Spain
Source: Eur Respir J 2001; 18: Suppl. 33, 49s
Year: 2001
Efficacy and safety of QVA149 compared with salmeterol/fluticasone combination (SFC) in Chinese patients with moderate-to-severe COPD: A subgroup analysis from the LANTERN study
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma
Source: Eur Respir J 2007; 29: 682-689
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept